Uso clínico de la fracción exhalada del óxido nítrico (FENO) en pacientes con asma. Recomendaciones basadas en síntesis de la evidencia

dc.contributorVásquez Hernández, Skarlet Marcell
dc.contributorVásquez Hernández, Skarlet Marcell [0001349039]
dc.contributorVásquez Hernández, Skarlet Marcell [es&oi=ao]
dc.contributorVásquez Hernández, Skarlet Marcell [0000-0003-2552-9819]
dc.contributorVásquez Hernández, Skarlet Marcell [Skarlet-Marcell-Vasquez-Hernandez-2194087164]
dc.creatorCano Rosales, Diana Jimena
dc.date.accessioned2022-09-09T20:37:07Z
dc.date.accessioned2023-06-12T20:38:40Z
dc.date.available2022-09-09T20:37:07Z
dc.date.available2023-06-12T20:38:40Z
dc.date.created2022-09-09T20:37:07Z
dc.date.issued2022
dc.identifierhttp://hdl.handle.net/20.500.12749/17615
dc.identifierinstname:Universidad Autónoma de Bucaramanga - UNAB
dc.identifierreponame:Repositorio Institucional UNAB
dc.identifierrepourl:https://repository.unab.edu.co
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/6663572
dc.description.abstractEl asma es una enfermedad heterogénea, clásicamente se define como una enfermedad inflamatoria crónica de las vías respiratorias que cursa con hiperrespuesta bronquial y una obstrucción variable al flujo aéreo. La fracción de óxido nítrico exhalado (FeNO) se ha propuesto como un biomarcador de diagnóstico, tratamiento y pronóstico en pacientes con asma, al estar relacionado con inflamación bronquial del fenotipo alérgico-T2, e inflamación eosinofílica. La Sociedad Americana de Tórax (American Thoracic Society ATS) en el año 2011 publico una guía de práctica clínica en donde se presentan las recomendaciones más importantes para la interpretación y aplicación clínica de la FeNO, a partir de entonces, las diferentes sociedades científicas a nivel local e internacional, han generado guías y recomendaciones para el uso de esta nueva tecnología, sin embargo, es importante identificar y analizar la evidencia científica en relación al uso de la FeNO en escenarios clínicos como lo son: diagnóstico, seguimiento e intervenciones farmacológicas.
dc.languagespa
dc.publisherUniversidad Autónoma de Bucaramanga UNAB
dc.publisherFacultad Ciencias de la Salud
dc.publisherMaestría en Métodos para la Producción y Aplicación de Conocimiento Científico en Salud
dc.relation1. Sociedad Española de Neumología y Cirugía Torácica. Guía Española para el Manejo del Asma (GEMA 5.1).
dc.relation2. Reddel HK, Bacharier LB, Bateman ED, Boulet L-P, Brightling C, Brusselle G, et al. GINA-Main-Report-2021-V2-WMS.pdf. 2021. p. 1–217.
dc.relation3. Turner SW, Chang AB, Yang IA. Clinical utility of exhaled nitric oxide fraction in the management of asthma and COPD. Breathe. 2019;15(4):306–16.
dc.relation4. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602– 15.
dc.relation5. Gil Torres. Epidemiología del asma en Colombia. Rev Colomb Neumol. 2015;27(3):223–5.
dc.relation6. Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest 2008; 133(2):343–9
dc.relation7. Gonzalez-Garcia M, Caballero A, Jaramillo C, Maldonado D, Torres-Duque CA. Prevalence, risk factors and underdiagnosis of asthma and wheezing in adults 40 years and older: A population-based study. J Asthma. 2015;52(8):823–30.
dc.relation8. Jia CE, Zhang HP, Lv Y, Liang R, Jiang YQ, Powell H, et al. The asthma control test and asthma control questionnaire for assessing asthma control: Systematic review and meta-analysis. J Allergy Clin Immunol. 2013;131(3):695–703
dc.relation9. Darcey J, Qualtrough A. Difficult-to-treat & severe Asthma in adolescent and adult patients - diagnosis and management. Glob Initiat Asthma. 2019;214:493– 509
dc.relation10. ALAT. Guía de práctica clínica Latinoamericana de asma grave 2020. Respirar 2020
dc.relation11. Hoyte FCL, Gross LM, Katial RK. Exhaled Nitric Oxide: An Update. Immunol Allergy Clin North Am 2018;38(4):573–85
dc.relation12. Measurement O. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912–30
dc.relation13. GINA-Main-Report-2021-FINAL-22-05-03-WMS.pdf.
dc.relation14. Wang Z, Pianosi PT, Keogh KA, Zaiem F, Alsawas M, Alahdab F, et al. The Diagnostic Accuracy of Fractional Exhaled Nitric Oxide Testing in Asthma: A Systematic Review and Meta-analyses. Mayo Clin Proc. 2018;93(2):191–8.
dc.relation15. Karrasch S, Linde K, Rücker G, Sommer H, Karsch-Völk M, Kleijnen J, et al. Accuracy of FENO for diagnosing asthma: A systematic review. Thorax. 2017;72(2):109–16.
dc.relation16. Kavanagh J, Jackson DJ, Kent BD. Over- and under-diagnosis in asthma. Breathe (Sheff). 2019 Mar;15(1):e20-e27. doi: 10.1183/20734735.0362-2018. PMID: 31031841; PMCID: PMC6481983.
dc.relation17. Sociedad Española de Neumología y Cirugía Torácica. Guía española para el manejo del asma GEMA 5.2
dc.relation18. Rupani H, Kent BD. Using Fractional Exhaled Nitric Oxide Measurement in Clinical Asthma Management. Chest. 2022;161(4):906–17.
dc.relation19. Harnan SE, Tappenden P, Essat M, Gomersall T, Minton J, Wong R, et al. Measurement of exhaled nitric oxide concentration in asthma: A systematic review and economic evaluation of NIOX MINO, NIOX VERO and Nobreath. Health Technol Assess (Rockv). 2015;19(82):1–330
dc.relation20. Yamashita M, Shibanai M, Sekimura K, Nitanai H, Ogasawara M, Kobayashi H, et al. Fractional exhaled nitric oxide levels as a predictor of long-term prognoses in patients with mild asthma. Respir Investig 2016;54(3):139–47
dc.relation21. Papakosta D, Latsios D, Manika K, Porpodis K, Kontakioti E, Gioulekas D. Asthma control test is correlated to Fev1 and nitric oxide in Greek asthmatic patients: Influence of treatment. J Asthma. 2011;48(9):901–6
dc.relation22. Quaedvlieg V, Sele J, Henket M, Louis R. Association between asthma control and bronchial hyperresponsiveness and airways inflammation: A crosssectional study in daily practice. Clin Exp Allergy. 2009;39(12):1822–9
dc.relation23. Shirai T, Furuhashi K, Suda T, Chida K. Relationship of the asthma control test with pulmonary function and exhaled nitric oxide. Ann Allergy, Asthma Immunol. 2008;101(6):608–13
dc.relation24. Global Initiative for Asthma Global Strategy for Asthma Management and Prevention. 2022
dc.relation25. Costa DD, Pitrez PM, Barroso NF, Roncada C. Asthma control in the quality of life levels of asthmatic patients’ caregivers: a systematic review with metaanalysis and meta-regression. J Pediatr (Rio J). 2019;95(4):401–9.
dc.relation26. Kimura H, Konno S, Makita H, Taniguchi N, Shimizu K, Suzuki M, et al. Prospective predictors of exacerbation status in severe asthma over a 3-year follow-up. Clin Exp Allergy. 2018;48(9):1137–46.
dc.relation27. Kupczyk M, ten Brinke A, Sterk PJ, Bel EH, Papi A, Chanez P, et al. Frequent exacerbators - a distinct phenotype of severe asthma. Clin Exp Allergy. 2014;44(2):212–21
dc.relation28. Price DB, Bosnic-Anticevich S, Pavord ID, Roche N, Halpin DMG, Bjermer L, et al. Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. Clin Transl Allergy. 2019;9(1):1–18
dc.relation29. Busse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med [Internet]. 2021;9(10):1165–73. Available from: http://dx.doi.org/10.1016/S2213-2600(21)00124-7
dc.relation30. Semprini R, Williams M, Semprini A, McDouall A, Fingleton J, Holweg C, et al. Type 2 Biomarkers and Prediction of Future Exacerbations and Lung Function Decline in Adult Asthma. J Allergy Clin Immunol Pract. 2018;6(6):1982-1988.e1
dc.relation31. Castillo JR, Peters SP, Busse WW. Asthma Exacerbations: Pathogenesis, Prevention, and Treatment. J Allergy Clin Immunol Pract. 2017;5(4):918–27.
dc.relation32. Blakey JD, Woolnough K, Fellows J, Walker S, Thomas M, Pavord ID. Assessing the risk of attack in the management of asthma: A review and proposal for revision of the current control-centred paradigm. Prim Care Respir J. 2013;22(3):344–52.
dc.relation33. Wang K, Verbakel JY, Oke J, Fleming-Nouri A, Brewin J, Roberts N, et al. Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: A systematic review and individual patient data meta-analysis. Eur Respir J. 2020;55(5).
dc.relation34. Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): A systematic review and meta-analysis. Thorax. 2018;73(12):1110–9
dc.relation35. Heffler E, Madeira LNG, Ferrando M, Puggioni F, Racca F, Malvezzi L, et al. Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma. J Allergy Clin Immunol Pract. 2018;6(3):776–81
dc.relation36. Hanania NA, Wenzel S, Roseń K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804– 11
dc.relation37. Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, et al. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. J Allergy Clin Immunol Pract. 2019;7(1):156-164.e1
dc.relation38. Shrimanker R, Keene O, Hynes G, Wenzel S, Yancey S, Pavord ID. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: A post hoc analysis. Am J Respir Crit Care Med. 2019;200(10):1308–12
dc.relation39. Hearn AP, Kavanagh J, d’Ancona G, Roxas C, Green L, Thomson L, et al. The relationship between FENO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract 2021;9(5):2093-2096.e1
dc.relation40. Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med. 2022;386(2):157–71
dc.relation41. Denton E, Price DB, Tran TN, Canonica GW, Menzies-Gow A, FitzGerald JM, et al. Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract 2021;9(7):2680-2688.e7
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rightsAbierto (Texto Completo)
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.titleUso clínico de la fracción exhalada del óxido nítrico (FENO) en pacientes con asma. Recomendaciones basadas en síntesis de la evidencia
dc.typeThesis


Este ítem pertenece a la siguiente institución